Concepts (63)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Drug Delivery Systems | 5 | 2021 | 1365 | 1.01 | Why? |
| Nanocapsules | 1 | 2021 | 54 | 0.85 | Why? |
| Theranostic Nanomedicine | 2 | 2019 | 143 | 0.85 | Why? |
| Drug Liberation | 1 | 2018 | 141 | 0.71 | Why? |
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 382 | 0.64 | Why? |
| Drug Carriers | 1 | 2021 | 590 | 0.56 | Why? |
| Extracellular Vesicles | 1 | 2021 | 607 | 0.53 | Why? |
| Polymers | 1 | 2018 | 507 | 0.52 | Why? |
| Water | 1 | 2018 | 765 | 0.51 | Why? |
| Multimodal Imaging | 1 | 2018 | 534 | 0.51 | Why? |
| Anti-HIV Agents | 1 | 2019 | 2209 | 0.31 | Why? |
| HIV-1 | 1 | 2019 | 3365 | 0.26 | Why? |
| Nanoparticles | 3 | 2019 | 2040 | 0.23 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.21 | Why? |
| Griseofulvin | 1 | 2018 | 14 | 0.19 | Why? |
| Hypromellose Derivatives | 1 | 2018 | 8 | 0.19 | Why? |
| Europium | 1 | 2018 | 15 | 0.19 | Why? |
| X-Ray Diffraction | 1 | 2018 | 249 | 0.17 | Why? |
| Solubility | 1 | 2018 | 382 | 0.17 | Why? |
| Drug Compounding | 1 | 2019 | 386 | 0.16 | Why? |
| Folic Acid | 1 | 2018 | 172 | 0.16 | Why? |
| Delayed-Action Preparations | 1 | 2018 | 291 | 0.16 | Why? |
| Microscopy, Confocal | 1 | 2018 | 343 | 0.16 | Why? |
| Oxazines | 1 | 2018 | 279 | 0.15 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 275 | 0.14 | Why? |
| Metagenomics | 1 | 2021 | 823 | 0.14 | Why? |
| Piperazines | 1 | 2018 | 445 | 0.14 | Why? |
| Nanotechnology | 1 | 2021 | 821 | 0.14 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 952 | 0.13 | Why? |
| Nanostructures | 1 | 2021 | 700 | 0.13 | Why? |
| Central Nervous System Diseases | 1 | 2019 | 410 | 0.13 | Why? |
| HIV Infections | 1 | 2019 | 11620 | 0.13 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.12 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.11 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3633 | 0.09 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.09 | Why? |
| Macaca mulatta | 1 | 2018 | 3716 | 0.09 | Why? |
| Animals | 4 | 2021 | 78931 | 0.08 | Why? |
| Macrophages | 1 | 2018 | 2784 | 0.07 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.07 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.07 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.06 | Why? |
| Brain | 1 | 2021 | 5133 | 0.06 | Why? |
| Drug Repositioning | 1 | 2021 | 5683 | 0.06 | Why? |
| Nervous System Diseases | 1 | 2020 | 4092 | 0.06 | Why? |
| Humans | 10 | 2021 | 930598 | 0.05 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.05 | Why? |
| Viral Vaccines | 1 | 2021 | 7560 | 0.05 | Why? |
| Magnetic Phenomena | 1 | 2019 | 148 | 0.05 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.04 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Surface Properties | 1 | 2019 | 448 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Tissue Distribution | 1 | 2019 | 483 | 0.04 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.02 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |